<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS190346</article-id><article-id pub-id-type="doi">10.1101/2023.10.26.564184</article-id><article-id pub-id-type="archive">PPR748494</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Magazine</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="fn" rid="FN1">†</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Tianyi</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="fn" rid="FN1">†</xref></contrib><contrib contrib-type="author"><name><surname>Bungwon</surname><given-names>Anang D.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>McGee</surname><given-names>Michael C.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yingying</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Veggiani</surname><given-names>Gianluca</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Weishan</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA</aff><aff id="A2"><label>2</label>Department of Mathematics, University of Houston, Houston, TX 77204, USA</aff><aff id="A3"><label>3</label>Division of Biotechnology and Molecular Medicine, Louisiana State University, Baton Rouge, LA, 70803, USA</aff><aff id="A4"><label>4</label>Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA</aff><author-notes><fn fn-type="equal" id="FN1"><label>†</label><p id="P1">These authors contributed equally to this work.</p></fn><corresp id="CR1">
<label>*</label>Correspondence: Address: 1909 Skip Bertman Drive, Baton Rouge, LA 70803, USA. <email>huang1@lsu.edu</email>; Tel.: +1-225-578-9467</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>01</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>27</day><month>10</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P2">Despite the success of global vaccination programs in slowing the spread of COVID-19, these efforts have been hindered by the emergence of new SARS-CoV-2 strains capable of evading prior immunity. The mutation and evolution of SARS-CoV-2 have created a demand for persistent efforts in vaccine development. SARS-CoV-2 Spike protein has been the primary target for COVID-19 vaccine development, but it is also the hotspot of mutations directly involved in host susceptibility and immune evasion. Our ability to predict emerging mutants and select conserved epitopes is critical for the development of a broadly neutralizing therapy or a universal vaccine. In this article, we review the general paradigm of immune responses to COVID-19 vaccines, highlighting the immunological epitopes of Spike protein that are likely associated with eliciting protective immunity resulting from vaccination. Specifically, we analyze the structural and evolutionary characteristics of the SARS-CoV-2 Spike protein related to immune activation and function via the toll-like receptors (TLRs), B cells, and T cells. We aim to provide a comprehensive analysis of immune epitopes of Spike protein, thereby contributing to the development of new strategies for broad neutralization or universal vaccination.</p></abstract><kwd-group><kwd>Broad Neutralization</kwd><kwd>COVID-19</kwd><kwd>Genetic Entropy</kwd><kwd>Glycosylation</kwd><kwd>Immune Epitope</kwd><kwd>Spike</kwd><kwd>Universal Vaccine</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P3">SARS-CoV-2, the etiological pathogen of COVID-19, is currently responsible for over 760 million cases of illness and 6.9 million deaths as of July 2023 <sup><xref ref-type="bibr" rid="R1">1</xref></sup>. As a single-stranded positive-sense betacoronavirus, SARS-CoV-2 exploits the host machinery for replication <sup><xref ref-type="bibr" rid="R2">2</xref></sup>. Spike protein is a key envelope glycoprotein for SARS-CoV-2 infection. The SARS-CoV-2 Spike protein assembles into trimers that can be broadly split into two subunits, S1 and S2, divided by a furin cleavage site (<xref ref-type="fig" rid="F1">Figure 1A</xref> &amp; <xref ref-type="fig" rid="F1">B</xref>). The S1 subunit is primarily responsible for initial angiotensin-converting enzyme 2 (ACE2) interaction and binding, while the S2 subunit enables membrane fusion <sup><xref ref-type="bibr" rid="R3">3</xref></sup>. The S1 subunit contains a receptor-binding site (RBD), which directly binds to ACE2, as well as an N-terminal domain (NTD), which is considered primarily structural in Spike function <sup><xref ref-type="bibr" rid="R4">4</xref></sup>. In contrast, the S2 domain contains two heptad repeat regions (HR1 and HR2) as well as a fusion peptide domain (FP) <sup><xref ref-type="bibr" rid="R5">5</xref></sup>. The FP acts immediately after the RBD-mediated Spike-ACE2 interaction by inserting itself into the host membrane, causing a drastic conformational change that brings the HR1 and HR2 domains into proximity with the cell membrane, leading to membrane fusion and viral internalization <sup><xref ref-type="bibr" rid="R6">6</xref></sup>.</p><p id="P4">Spike protein recognizes and binds to targeted host receptors, predominantly ACE2 receptor <sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R7">7</xref></sup>, initiating viral entry into host cells via endocytosis. After entry, the viral RNA escapes the host endosome and exploits the translational machinery of the cell for viral protein production <sup><xref ref-type="bibr" rid="R8">8</xref></sup>, followed by assembly and release of the virions from the host cells <sup><xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R10">10</xref></sup> (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Since it relies on the translational mechanisms of host cells, Spike protein is subject to post-translational modifications (PTMs), which may alter Spike-mediated host-virus interactions and host immune responses. Particularly, glycosylation, the addition of glycan molecules to a protein, has been demonstrated to affect the interaction of a variety of biomolecules with Spike protein <sup><xref ref-type="bibr" rid="R11">11</xref></sup>.</p><p id="P5">Since the identification of its role in the initiation of SARS-CoV-2 infection, Spike protein has been of interest to the scientific community as a primary target for vaccine design and therapeutics <sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R12">12</xref>–<xref ref-type="bibr" rid="R14">14</xref></sup>. The Spike-based vaccine-elicited host immune cell responses can be broadly divided into three arms: innate immune response, in part as a result of toll-like receptor (TLRs) recognition; T cell response; and B cell response <sup><xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R20">20</xref></sup>. In brief, innate receptor ligands such as TLR ligands in the vaccine can activate innate immune cells, particularly antigen-presenting cells (APCs), which further prime the activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Among the activated CD4<sup>+</sup> T cells, follicular helper T (Tfh) cells contribute to B cell activation, plasma cell maturation, and antibody production, while type 1 helper T (Th1) cells help potentiate APC function, CD8<sup>+</sup> T cell activation, and cytotoxicity. The vaccine-elicited antibodies provide protection through the neutralization of viruses, while the cytotoxic T lymphocytes (CTLs) eliminate infected host cells to promote clearance of infections (<xref ref-type="fig" rid="F2">Figure 2</xref>). The immune subset specialization is heavily influenced by the vaccine adjuvants, while the specificity of the vaccine-elicited antibodies and CTLs is largely defined by the antigenic immune epitopes of the vaccine <sup><xref ref-type="bibr" rid="R21">21</xref>,<xref ref-type="bibr" rid="R22">22</xref></sup>.</p><p id="P6">Host-virus interactions mediated by Spike protein appear to be the primary driver of SARS-CoV-2 evolution <sup><xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup>. In the three-year period following the initial outbreak of COVID-19, most circulating SARS-CoV-2 strains have accumulated upwards of 40 mutations in their Spike proteins. Given that most vaccinations administered to the global population specifically target Spike proteins, this may in part explain the sharp decrease in vaccine efficacy over a relatively short period of time <sup><xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref></sup>. With cases of breakthrough SARS-CoV-2 infections in vaccinated populations increasing recently <sup><xref ref-type="bibr" rid="R27">27</xref></sup>, it has become apparent that the development of universal vaccines that are resilient against emerging SARS-CoV-2 variants will be required moving forward.</p><p id="P7">A universal vaccine is largely defined as one that is safe, long-lasting, and effective against multiple variants <sup><xref ref-type="bibr" rid="R28">28</xref></sup>. A detailed understanding of the underlying factors of host immune responses to SARS-CoV-2 is critical for the development of a universal COVID-19 vaccine. Here, we explore the characteristics of immunogenic epitopes on Spike protein, aiming to identify regions of the SARS-CoV-2 Spike protein that are of particular interest in the context of universal vaccine development. Specifically, we explore the interactions between Spike immunogenic motifs and immune receptors on APCs, T cells, and B cells and discuss the efficacy and sustainability of specific T and B cell immune epitopes for universal vaccine development.</p><sec id="S2"><title>Interactions of SARS-CoV-2 Spike protein with Toll-like receptors</title><p id="P8">TLRs direct the activation and localization of cells of the innate immune system, ultimately governing the initial host response to both infection and vaccination. Following SARS-CoV-2 infection or the administration of therapeutics that directly or indirectly introduce SARS-CoV-2 Spike protein into a host system, an innate immune response is initiated, in part, via TLR activity <sup><xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup>. Although this reaction is integral to the host immune response, multiple studies have shown excessive TLR activation to be a driver of uncontrolled inflammation and ultimately tissue injury upon host exposure to SARS-CoV-2 <sup><xref ref-type="bibr" rid="R30">30</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup>. In the context of SARS-CoV-2 therapies, cell-surface TLRs that are capable of recognizing glycolipids, proteins, and peptides (such as those in SARS-CoV-2 Spike) are of particular importance. The involvement of TLRs, including TLR1, TLR4, and TLR6, in COVID-19 pathogenesis has been demonstrated <sup><xref ref-type="bibr" rid="R30">30</xref>–<xref ref-type="bibr" rid="R33">33</xref></sup>. TLR2 primarily recognizes lipoproteins, and its role in SARS-CoV-2 Spike interaction has been suggested to be minor and partially dependent on the formation of heterodimers with both TLR1 and TLR6 <sup><xref ref-type="bibr" rid="R34">34</xref></sup>. Patients with severe COVID-19 have been demonstrated to have high serum levels of cytokines downstream of the MyD88 signal cascade <sup><xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R35">35</xref></sup>. Additionally, vaccines with supplemental adjuvants targeting TLR1 and TLR4 have been demonstrated to provide a higher level of protection as compared to controls <sup><xref ref-type="bibr" rid="R36">36</xref>–<xref ref-type="bibr" rid="R38">38</xref></sup>.</p><p id="P9">Structure-based predictions have suggested that multiple Spike residues likely interact with TLR1, TLR4, and TLR6 (<xref ref-type="fig" rid="F3">Figure. 3A-C</xref>) <sup><xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R46">46</xref></sup>. Tthe sites predicted to be involved in direct interaction with TLRs are predominantly located in the Spike S1 subunit flanking the RBD, including the NTD and regions to the C terminus of RBD on the S1. Note that there is no preference toward hydrophobic or hydrophilic interaction (<xref ref-type="fig" rid="F3">Figure 3D</xref>). All residues interacting with TLR1 and TLR6 can be found within the Spike S1 subunit, with a particular density within regions 30-117 and 204-306. Notably, the Shannon entropy (SE), which represents the degree of genetic variation between all SARS-CoV-2 variants of all residues within this region, is very low, with no single residue exceeding 0.05, even when exclusively considering the Omicron BA.5 lineage (<xref ref-type="fig" rid="F3">Figure 3D</xref>). Low genetic entropy indicates a low rate of genetic variability within this region, suggesting that TLR-interacting residues are relatively conserved. Therefore, it is likely that vaccine-elicited immune responses to these regions may induce cross-reactive and long-lasting protection even in the occurrence of new variants.</p><p id="P10">The described regions are expected to interact with TLRs and help induce an enhanced initial response of APCs that is conducive to higher vaccine efficacy. Although this enhanced initial response may often be beneficial in eliciting host immunity against viruses, hyperinflammation has repeatedly been associated with adverse reactions to vaccination as well as severe COVID-19 <sup><xref ref-type="bibr" rid="R47">47</xref>–<xref ref-type="bibr" rid="R49">49</xref></sup>. Therefore, in addition to their potential benefits, these TLR-interacting motifs should also be considered for potential vaccine-associated adverse effects. The inclusion of TLR agonists as adjuvants has been a popular strategy in vaccine development, with numerous demonstrated successes <sup><xref ref-type="bibr" rid="R50">50</xref>,<xref ref-type="bibr" rid="R51">51</xref></sup>. It is, however, critical to understand the agonistic properties of endogenous TLRs in vaccine antigens to guide the selection of additional adjuvants for emerging diseases. While the inclusion of TLR agonists is likely beneficial to vaccine efficacy for most populations, they pose a potential danger of provoking vaccine-associated acute inflammation mediated by an excessive innate immune response.</p></sec><sec id="S3"><title>T cell epitopes of SARS-CoV-2 Spike protein</title><p id="P11">Being a primary driver of the adaptive immune response, T cells modulate humoral and cellular immunity to SARS-CoV-2 infection and play a critical role in the maintenance of long-term SARS-CoV-2 immunity <sup><xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R52">52</xref>,<xref ref-type="bibr" rid="R53">53</xref></sup>. Studies have demonstrated the persistence of T cell-mediated immune responses between SARS-CoV-2 variants of concern (VOCs) <sup><xref ref-type="bibr" rid="R54">54</xref>–<xref ref-type="bibr" rid="R56">56</xref></sup>, including the Omicron BA.5 strain <sup><xref ref-type="bibr" rid="R57">57</xref></sup>. This cross-reactive T cell immunity may be the primary driver of resistance to these newer strains conferred by early COVID-19 vaccines, suggesting a critical role of T cell immune epitopes for universal vaccine development.</p><p id="P12">As T cells primarily act to limit viral replication by mediating APC activation, humoral immune response, and destruction of infected cells (<xref ref-type="fig" rid="F2">Figure 2</xref>), they likely do not prevent SARS-CoV-2 infection. Although the prevention of disease is the ideal outcome of vaccination, the prevention of severe clinical manifestations and the further spread of disease is also a desirable result <sup><xref ref-type="bibr" rid="R58">58</xref></sup>. This assertion is bolstered by the greatly decreased incidence of hospitalization for vaccinated patients upon clinical presentation of COVID-19 following Omicron infection, despite having received vaccination for non-Omicron SARS-CoV-2 lineages <sup><xref ref-type="bibr" rid="R59">59</xref>–<xref ref-type="bibr" rid="R61">61</xref></sup>.</p><p id="P13">T cells primarily recognize short, linear peptides ranging from 8 – 15 amino acids in length presented on human leukocyte antigen (HLA) molecules <sup><xref ref-type="bibr" rid="R62">62</xref>,<xref ref-type="bibr" rid="R63">63</xref></sup>. There are two major HLA groups, class I and class II, which present antigens predominantly to the T cell receptors (TCRs) of CD8<sup>+</sup> and CD4<sup>+</sup> T cells, respectively <sup><xref ref-type="bibr" rid="R64">64</xref>,<xref ref-type="bibr" rid="R65">65</xref></sup>. Class II HLA complexes are typically found only on APCs and present peptides from exogenous sources, while class I HLA complexes are expressed ubiquitously and recognize peptides from endogenous antigens <sup><xref ref-type="bibr" rid="R65">65</xref></sup>. The linear nature of T cell immune epitopes decreases the complexity of vaccine development targeting T cell receptors, as variation in protein/peptide structure is of minimal concern. However, TCR recognizes peptide antigens only if they are presented by the HLA. HLA genes are expressed in a polymorphic manner, and various populations may be deficient in a specific HLA group <sup><xref ref-type="bibr" rid="R66">66</xref>,<xref ref-type="bibr" rid="R67">67</xref></sup>. It is speculated that the outcome of TCR-stimulating vaccines is heterogenous, but a potential cross-reactive long-term effect may be achieved in some individuals. A potential strategy to cope with the HLA genetic variance is to identify peptide sequence combinations expressed by the majority of the global population (with some combinations capable of exceeding 99% global population coverage) <sup><xref ref-type="bibr" rid="R68">68</xref>–<xref ref-type="bibr" rid="R71">71</xref></sup>.</p><p id="P14">While the binding of a peptide to HLA complex is necessary for the initiation of a T cell response, this is not sufficient. Bioinformatic analysis of T cell epitopes (compiled at the Immune Epitope Database, IEDB) shows a relatively narrow epitope repertoire for T cells as compared to HLA complexes <sup><xref ref-type="bibr" rid="R72">72</xref>,<xref ref-type="bibr" rid="R73">73</xref></sup>. As of July 2023, a query in IEDB shows a pervasive subset of T cell epitopes (having occurred in ten or more individuals and taking place in over 80% of individuals tested for these epitopes), as demonstrated by the proportion of their incidence among individuals who have been tested for them (<xref ref-type="fig" rid="F4">Figure 4A</xref>&amp;<xref ref-type="fig" rid="F4">B</xref>). Interestingly, 9 of these 21 peptides show high average levels of genetic entropy (with a Shannon entropy exceeding 0.05), suggesting that T cell interaction could contribute to SARS-CoV-2 evolution (<xref ref-type="fig" rid="F4">Figure 4A</xref>). These 9 epitopes all fall within the NTD and RBD. Structurally both RBD and NTD are critical in SARS-CoV-2 interactions with host receptors. Mutations in S1 including the NTD and RBD are abundant <sup><xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R24">24</xref></sup>, likely due to their active involvement in host-virus interaction that cause selection pressure imposed host receptors (notably ACE2) and antibodies. Conversely, T cell epitopes in the Spike S2 subunit (residues 751- 767, 936-952, 1011-1028, and 1171-1179) exhibit comparatively lower rates of genetic variability, likely because S2 domain is less engaged in direct interactions between the virus and host receptor/antibodies. Given the relatively low genetic variability, TCR epitopes falling within the S2 region may be target candidates of cross-reactive T cell memory responses for universal vaccine development.</p></sec><sec id="S4"><title>B cell epitopes of SARS-CoV-2 Spike protein</title><p id="P15">B cells play a critical role in the adaptive immune response arising from SARS-CoV-2 infection <sup><xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R74">74</xref>,<xref ref-type="bibr" rid="R75">75</xref></sup>. B cells have functions including cytokine production, the secretion of neutralizing antibodies, and antigen presentation. In the context of COVID-19, the primary known protective role of B cells is the secretion of neutralizing antibodies to prevent both initial infection and viral propagation <sup><xref ref-type="bibr" rid="R76">76</xref></sup>. Neutralizing antibodies act by binding SARS-CoV-2, primarily Spike protein, and preventing cellular entry of viral particles by sterically blocking their interaction with the host receptors <sup><xref ref-type="bibr" rid="R77">77</xref>,<xref ref-type="bibr" rid="R78">78</xref></sup>. Anti-Spike antibodies have been the primary scientific focus of COVID-19 pathology and therapeutic development <sup><xref ref-type="bibr" rid="R79">79</xref>–<xref ref-type="bibr" rid="R81">81</xref></sup>. Experimental analysis of patient sera samples has been used to classify antibodies that are commonly found in individuals infected with SARS-CoV-2. Bioinformatic analysis of anti-Spike binding antibodies revealed over 4,000 antibodies with distinct antigen binding sites that have been isolated from human sera <sup><xref ref-type="bibr" rid="R72">72</xref></sup>. While multiple regions of the Spike protein are capable of eliciting antibody responses, only a small subset of these antibodies appears to be capable of inhibiting SARS-CoV-2 infection when used in neutralization assays. The identification of neutralizing antibody epitopes, especially broadly neutralizing antibody epitopes, will aid the development of future therapeutics and universal vaccines.</p><p id="P16">To best summarize the SARS-CoV-2 Spike protein epitopes recognized by patients’ antibodies, we queried the IEDB database and further cross-referenced our search for antibodies whose neutralizing activity was validated via <italic>in vitro</italic> neutralization assays. This analysis highlighted the distribution and frequency of serum anti-Spike antibodies having linear epitopes as well as the position of each recognized epitope (<xref ref-type="fig" rid="F5">Figure 5</xref>). Notably, a large number of the observed antibodies targeted regions throughout the RBD of SARS-CoV-2 Spike protein (<xref ref-type="fig" rid="F5">Figure 5A</xref>). However, this observation may partially result from sampling bias created by higher rates of database deposition for antibodies that are found to have neutralizing activity due to their binding to the RBD. Nonetheless, when we compared the relative propensity of regions to which classified serum antibodies bind SARS-CoV-2 Spike protein and the locations of antibody binding sites that have been experimentally validated to effectively neutralize SARS-CoV-2 (<xref ref-type="fig" rid="F5">Figure 5B</xref>), there appear to be only three recurring regions to which patient serum antibodies bind and effectively neutralize SARS-CoV-2, the majority of which occur outside of Spike protein’s RBD (<xref ref-type="fig" rid="F5">Figure 5B</xref>). Taking into consideration the genetic entropy and solvent accessibility of these regions, many of the epitopes recognized by patients’ antibodies have high solvent accessibility and experience high rates of mutation within the RBD (<xref ref-type="fig" rid="F5">Figure 5B</xref>). This observation closely aligns with the notion that mutations in the RBD of SARS-CoV-2 play a part in immune escape from antibody neutralization and thus viral evolution. Interestingly, the neutralizing epitopes of Spike protein that are located outside the RBD appear to be conserved (low genetic entropy), despite their intermediate to high solvent accessibility. In particular, epitopes in the S2 domain (spanning residues 809-876 and 1140-1166) displayed low genetic entropy, high solvent accessibility, and were commonly recognized by patients’ antibodies resulting in good neutralization (<xref ref-type="fig" rid="F5">Figure 5B</xref>&amp;<xref ref-type="fig" rid="F5">C</xref>). Therefore, such epitopes would likely be promising targets for universal vaccine development as patient antibodies targeting these areas would likely be abundant, highly neutralizing, and less likely to lose effectiveness against newly emerging SARS-CoV-2 lineages.</p></sec><sec id="S5"><title>Glycosylation in SARS-CoV-2 Spike immune epitopes</title><p id="P17">Glycosylation is the most common post-translational modification (PTM) occurring within most organisms. During the process of glycosylation, carbohydrate molecules are covalently attached to the side chains of a number of amino acids <sup><xref ref-type="bibr" rid="R82">82</xref>,<xref ref-type="bibr" rid="R83">83</xref></sup>. Most commonly, this occurs at either oxygen (in Ser, Thr and Tyr) or nitrogen (in Arg and Asn), resulting in O-glycosylation and N-glycosylation, respectively. In eukaryotes, O-glycosylation occurs primarily in the Golgi apparatus, while N-glycosylation occurs primarily in the endoplasmic reticulum <sup><xref ref-type="bibr" rid="R84">84</xref>,<xref ref-type="bibr" rid="R85">85</xref></sup>. The reasons for which a protein may undergo glycosylation are multifaceted. The added carbohydrate motifs can function as adhesion molecules via interaction with cellular lectins, which may ultimately drive the transportation and sub-cellular location of the modified proteins <sup><xref ref-type="bibr" rid="R86">86</xref>,<xref ref-type="bibr" rid="R87">87</xref></sup>. Glycans may also obscure the presentation of surface molecules, which may alter the antigenicity of proteins and peptides presented by various pathogens <sup><xref ref-type="bibr" rid="R88">88</xref>,<xref ref-type="bibr" rid="R89">89</xref></sup>. Finally, glycosylation can substantially alter the structural presentation of a protein by influencing its local conformation as well as its thermostability <sup><xref ref-type="bibr" rid="R90">90</xref>,<xref ref-type="bibr" rid="R91">91</xref></sup>. During the production of SARS-CoV-2 proteins in host cells (<xref ref-type="fig" rid="F1">Figure 1C</xref>), the host molecular machinery also heavily glycosylates viral proteins, including Spike protein. In total, the SARS-CoV-2 Spike protein has been predicted to contain as many as 27 glycosites (predominantly N-glycosylation), the majority of which have been confirmed by mass spectroscopy (<xref ref-type="fig" rid="F6">Figure 6A</xref>&amp;<xref ref-type="fig" rid="F6">B</xref>)<sup><xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R92">92</xref>–<xref ref-type="bibr" rid="R94">94</xref></sup>.</p><p id="P18">Due to their size, glycans substantially alter the surface accessibility of the residues to which they are attached. This steric hindrance has major consequences for epitope accessibility and ultimately the manner in which a protein is engaged by the human immune system, especially for antibody binding <sup><xref ref-type="bibr" rid="R95">95</xref>,<xref ref-type="bibr" rid="R96">96</xref></sup>. A comparison of glycosites found on the SARS-CoV-2 Spike protein within immunologically relevant sites reveals that glycosylation occurs at several sites recognized by the immune system. For example, the N801 glycosite falls within a B cell epitope (along with predicted glycosites S673 and N1158) (<xref ref-type="fig" rid="F6">Figure 6A</xref>). N657 might interact with TLR4, though this interaction has only been demonstrated computationally (<xref ref-type="fig" rid="F3">Figure 3D</xref>). Note that the majority of the glycosites (23 of 27) in Spike protein are highly conserved (see genetic entropy, <xref ref-type="fig" rid="F6">Figure 6A</xref>). This conservation may be a result of these glycosites having structural and/or functional roles within the SARS-CoV-2 Spike protein.</p><p id="P19">Interestingly, N801 has been consistently confirmed as glycosylated <sup><xref ref-type="bibr" rid="R92">92</xref></sup> and demonstrated as a potent epitope for antibody recognition, including IgG and IgA <sup><xref ref-type="bibr" rid="R72">72</xref></sup> (<xref ref-type="fig" rid="F6">Figure 6A</xref>). Notably, this glycosite is located within the fusion peptide (FP) (<xref ref-type="fig" rid="F6">Figure 6A</xref>) and is also proximal to a region that has been frequently targeted by neutralizing antibodies in the S2 domain (<xref ref-type="fig" rid="F5">Figure 5 A</xref>&amp;<xref ref-type="fig" rid="F5">B</xref>). An important observation is that the immune epitope containing N801 is well conserved (low genetic entropy) in all VOCs, which is likely associated with its location within the FP region of the S2 domain. The FP is required for virus-cell membrane fusion during viral entry and functionally conserved in coronaviruses <sup><xref ref-type="bibr" rid="R97">97</xref></sup>, making it a promising candidate epitope for broad neutralization and universal vaccine design.</p><p id="P20">In addition to residue N801, several other locations should be noted. Glycosylation sites N61, N74, N149, N165, N343, and N1074 overlap with regions known to engage in TCR interaction, while S673 and N1158 also fall within regions known to elicit neutralization upon antibody binding (<xref ref-type="fig" rid="F6">Figure 6A</xref>). Particularly, N1158 falls within a region frequently validated as neutralizing antibody epitope (see <xref ref-type="fig" rid="F5">Figure 5B</xref>). It should be noted that not all glycosites are confirmed by mass spectrometry (MS), with O-linked glycosites being particularly erratic in their identification by MS <sup><xref ref-type="bibr" rid="R93">93</xref>,<xref ref-type="bibr" rid="R98">98</xref>–<xref ref-type="bibr" rid="R101">101</xref></sup>.</p></sec><sec id="S6"><title>Consideration of Spike immune epitopes in universal vaccine development</title><p id="P21">Taken together, our analyses suggest that regions proximal to N149, N165, N343, N801, and N1158 are immunogenic and relatively conserved. These regions process immune epitopes that can interact with TCRs or immunoglobulins and have low genetic entropy, making them promising antigens for universal vaccine development. Moreover, these regions benefit from low genetic entropy, likely resulting from the structural and/or functional roles of these glycosites.</p><p id="P">Such a relative conservation would likely reduce the probability of escape from vaccine-induced immunity by future SARS-CoV-2 variants. However, it is possible that this very same glycosylation may also play significant roles in host-virus interactions and the immune responses mounted against these sites. Therefore, it is important to further investigate the effects of glycosylation in peptide-based vaccines targeting these regions, as the presence or absence of a glycan molecule may substantially alter T cell recognition and/or antibody binding. Comparative studies of peptide-based vaccines that include glycosylated versus deglycosylated antigens will provide valuable insights into the impact of glycosylation on vaccine efficacy and immune response.</p><p id="P22">When it comes to selecting vaccine antigens, it is essential to consider both the immunogenicity of the ‘naked’ antigens as well as their post-translational modifications, as they significantly influence the function and interaction of proteins with the immune system. An example of such steric alterations can be observed in B cell epitopes of the SARS-CoV-2 Spike protein. Linear epitope prediction of the SARS-CoV-2 Spike sequence reveals a wide array of potential binding targets. Nonetheless, it is crucial to assess these targets in the context of their surface accessibility, which contributes to their potential for interaction with immune receptors, especially antibodies. The relative capability of a peptide sequence to bind antibodies can be approximated by multiplying its relative antigenicity by its relative surface accessibility <sup><xref ref-type="bibr" rid="R102">102</xref></sup>. To further compare the immunogenicity of the glycosylated and non-glycosylated Spike regions, we computed the relative antigenicity of each spike region using methods adapted from Sikora <italic>et al</italic><sup><xref ref-type="bibr" rid="R102">102</xref></sup>. Such computational analyses revealed minimal differences in the predicted immunogenicity of the non-glycosylated versus glycosylated epitopes for eliciting B cell responses (<xref ref-type="fig" rid="F6">Figure 6C</xref>).</p><p id="P23">However, recent studies comparing deglycosylated and fully glycosylated Spike proteins in immunizations of hamsters and mice found that the deglycosylated Spike protein led to enhanced protective immunity <sup><xref ref-type="bibr" rid="R103">103</xref></sup>. Furthermore, removal of glycosites in the RBD or especially in the S2 domain resulted in the exposure of more conserved epitopes in both regions, eliciting broadly protective immunity <sup><xref ref-type="bibr" rid="R104">104</xref></sup>. These effects may be, in part, contributed by the better accessibility and/or altered stability of the peptide epitopes in the ‘naked’ Spike protein.</p></sec></sec><sec id="S7" sec-type="discussion"><title>Discussion</title><p id="P24">A robust understanding of SARS-CoV-2 Spike immune epitopes is critical for the development of universal vaccines and broadly effective therapies that target the Spike protein. Our analysis demonstrates that while an immunological response is observed against nearly every portion of SARS-CoV-2 Spike, only a fraction of these sites elicits a response that is effective in preventing SARS-CoV-2 infection. This observation demonstrates that vaccination using proteins or peptides that target the entirety of Spike protein is likely a less optimal solution when compared to the use of pools of immunogenic epitopes. Such a strategy may not only produce an enhanced immune response to current SARS-CoV-2 variants but will likely provide a stronger and/or more sustainable immunity to emerging SARS-CoV-2 lineages. Our bibliographic and computational analyses indicate that the bulk of a physiologically relevant immune response can likely be elicited by the administration of a subset of Spike protein peptides such as 1-74, 204-256, 445-495, 789-876, and 1140-1179 (<xref ref-type="fig" rid="F6">Figure 6D</xref>). Regions 1-74 and 204-256 benefit from having strong interactions with both TLRs and T cells. Regions 445-495 and 1140-1179 contain linear epitopes for neutralizing antibodies and TCR interactions. Both 789-876 and 1140-1179 (<xref ref-type="fig" rid="F5">Figure 5B</xref>) benefit from high solvent accessibility and very low relative genetic entropy. The low genetic entropy of these regions suggests that these regions are relatively well-conserved among SARS-CoV-2 variants and unlikely to escape immunorecognition even in the case of novel VOCs. The presence of two glycosylation sites within 1140-1179 makes it less susceptible to mutations. Similarly, region 789-876, housing the glycosite N801 and Fusion Peptide (FP) domain, is likely to remain well-conserved.</p><p id="P25">SARS-CoV-2 will continue to evolve, and new vaccines to address emerging variants will be needed. This demand will call for the creation of novel vaccines that are effective against a wide range of SARS-CoV-2 variants as opposed to a specific strain. COVID-19 vaccine-elicited antibody responses are critical for protective immunity, but they wane rapidly within a year post-vaccination <sup><xref ref-type="bibr" rid="R105">105</xref></sup>. Antigen-specific T cells do not block the initial infection, but induction of T cells specific against conserved domains of SARS-CoV-2 Spike protein demonstrated potential in protecting against SARS-CoV-2 variants that escaped antibody neutralization <sup><xref ref-type="bibr" rid="R106">106</xref></sup>. We speculate that administration of peptide pools encompassing regions within the SARS-CoV-2 Spike protein that are conserved and immunogenic, and that can interact with TLRs, TCR and antibodies, will likely produce broad protection from SARS-CoV-2 variants. An important consideration in the design of universal vaccines targeting immunogenic Spike regions would be the potential overlap of these Spike regions with autoantigens. New onsets of autoimmune diseases have been reported post-COVID-19 infection or vaccination <sup><xref ref-type="bibr" rid="R107">107</xref>,<xref ref-type="bibr" rid="R108">108</xref></sup>, although the underlying mechanisms are unclear. There is an urgent need to further identify and characterize the immune epitopes that overlap with human self-antigens, including self-encoded nucleic acids and proteins, post-translational modifications, and epitopes in the commensal microbiome. Autoantigen-overlapping epitopes should be excluded from future vaccine designs to avoid vaccine-induced adverse effects. Vaccines that contain an enriched pool of conserved and immunogenic epitopes, while avoiding glycosites and autoantigen overlaps will likely not only improve clinical outcomes, but also provide enhanced protection, decrease healthcare costs, improve patient satisfaction, and limit vaccine-associated autoimmune effects.</p></sec><sec id="S8" sec-type="methods"><title>Methods</title><sec id="S9"><title>Genetic entropy analysis</title><p id="P26">The genetic variability within individual amino acids of SARS-CoV-2 was measured using the Shannon entropy (SE) of codons occurring at the indicated positions. The Shannon entropy value was denoted as ‘genetic entropy’ and was retrieved using the NextStrain (<ext-link ext-link-type="uri" xlink:href="https://nextstrain.org/">nextstrain.org</ext-link>) COVID analysis tool. Data used for this analysis was obtained from the aligned sequence of SARS-CoV-2 genomes reposited in the GISAID (<ext-link ext-link-type="uri" xlink:href="https://gisaid.org/">gisaid.org</ext-link>) as of July 2023. For peptide sequences, the average genetic entropy value of codons throughout the peptide was calculated and reported as ‘mean genetic entropy’. The genetic entropy of all reposited sequences, and the sequences of the BA.5 Omicron lineage, were reported separately.</p></sec><sec id="S10"><title>Solvent accessibility analysis</title><p id="P27">Solvent accessibility refers to the solvent-accessible surface area (SASA) of indicated individual amino acids. This value was calculated using the PyMOL by the “Get_area” function, which calculates the surface area in square Angstroms of the selection given with default setting (dot density = 2, solvent radius = 1.4 angstroms, dot_solvent = true). This function was performed for each resolved residue within the closed-state SARS-CoV-2 spike protein (6VXX). For peptides, average solvent accessibility (total solvent accessibility of all resolved residues within the peptide divided by the total number of resolved residues) was denoted as ‘mean solvent accessibility’.</p></sec><sec id="S11"><title>Experimentally validated epitope determination and frequency of response</title><p id="P28">Data from the Immune Epitope Database (<ext-link ext-link-type="uri" xlink:href="https://iedb.org/">IEDB.org</ext-link>) was used for the determination of experimentally validated T and B cell epitopes <sup><xref ref-type="bibr" rid="R109">109</xref></sup>. T cell epitopes were queried using SARS-CoV-2 Spike sequence as the epitope source and searching for epitopes that had positive outcomes in T cell assays. These results were further filtered by having human origin, occurring within SARS-CoV-2 and Spike protein, and having linear epitopes. The database was then queried for patient sera samples that had been tested for T cell epitope propensity. The frequency of response for each epitope was calculated by dividing the total number of positive tests by the overall test number. Epitopes demonstrating a frequency of response exceeding 80% and having ten or more reposited tested individuals were reported. Experimentally validated neutralizing B cell epitopes were found by querying the database for SARS-CoV-2 anti-spike antibodies of human origin that have also been tested for SARS-CoV-2 neutralizing capabilities. The linear epitopes of samples meeting these criteria and showing successful neutralization in over 50% of tests were reported. Calculation of the propensity of occurrence for all binding antibodies was performed by querying IEDB for all human-origin antibodies demonstrating SARS-CoV-2 spike binding capacity. Data retrieved July 2023.</p></sec><sec id="S12"><title>IgG/IgA overlap calculation</title><p id="P29">Data from the Immune Epitope Database (<ext-link ext-link-type="uri" xlink:href="https://iedb.org/">IEDB.org</ext-link>) was used to calculate the relative propensity for immunoglobulin binding to various Spike regions. A database export containing linear epitopes of human-derived antibodies to SARS-CoV-2 spike between 4-20 amino acids was processed through IgPred Server (iiitd.edu) <sup><xref ref-type="bibr" rid="R110">110</xref></sup> and the resulting IgG/IgA propensity score was reported. Value for each residue has been reported as the mean score for fragments overlapping the target area. Data were retrieved in July 2023.</p></sec><sec id="S13"><title>B cell epitope antigenicity prediction</title><p id="P30">B cell epitope antigenicity prediction was performed based on methods used by Sikora <italic>et al</italic> 2021. Accessibility analysis over the SARS-CoV-2 Spike protein (PDB: 6VXX) was performed by rigid-body docking of the Fab fragment of antibody CR3022 <sup><xref ref-type="bibr" rid="R111">111</xref></sup>. This analysis was performed on both the native Spike structure as well as the same Spike structure having had its glycans excluded from the model. BepiPred 2.0 webserver was used for the prediction of linear B cell epitopes <sup><xref ref-type="bibr" rid="R112">112</xref></sup>. The outputs of these analyses were then multiplied across their respective residues. The maximal output value was then set as 1, and all other values were normalized to the maximum across the entire data set to produce epitope scores for all residues in the predicted epitope regions.</p></sec></sec></body><back><ack id="S15"><title>Acknowledgement</title><p>This work was supported in part by grants from the National Institutes of Health (P20 GM130555, R21 AI166898, and R01 AI151139) and a Big Idea Research Grant from the Provost’s Fund for Innovation in Research at Louisiana State University. W.H. received a Research Publication Grant in Engineering, Medicine, and Science from the American Association of University Women.</p></ack><sec id="S14" sec-type="data-availability"><title>Data availability</title><p id="P31">The findings of this study are based on metadata reposited within the GISAID (<ext-link ext-link-type="uri" xlink:href="https://gisaid.org/">gisaid.org</ext-link>) and IEDB (<ext-link ext-link-type="uri" xlink:href="https://iedb.org/">iedb.org</ext-link>) databases as of July 2023. The furin-cleaved spike protein of SARS-CoV-2 with one RBD erect structure (PDB, 6VXX) was used to present the 3D structure of Spike protein in this article. The PyMOL Molecular Graphics System, Version 2.0, Schrödinger, LLC, New York, NY, USA) was used for structural analysis and rendering.</p></sec><fn-group><fn fn-type="con" id="FN2"><p id="P32"><bold>Author Contributions</bold></p><p id="P33">N.M. and T.Z. analyzed and interpreted data, made the figures, and wrote the manuscript; G.V., Y.W., M.C.M., and A.D.B. reviewed and edited the manuscript; W.H. conceived the research, secured funding, made the figures, and wrote the manuscript. All authors approved the final version of the manuscript.</p></fn><fn id="FN3" fn-type="conflict"><p id="P34"><bold>Conflicts of Interest</bold></p><p id="P35">W.H. received research support from MegaRobo Technologies Co., Ltd., which was not used in this study. The other authors claim no conflicts of interest.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>E</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Gardner</surname><given-names>L</given-names></name></person-group><article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title><source>Lancet Infect Dis</source><year>2020</year><volume>20</volume><fpage>533</fpage><lpage>534</lpage><pub-id pub-id-type="pmcid">PMC7159018</pub-id><pub-id pub-id-type="pmid">32087114</pub-id><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30120-1</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandersen</surname><given-names>S</given-names></name><name><surname>Chamings</surname><given-names>A</given-names></name><name><surname>Bhatta</surname><given-names>TR</given-names></name></person-group><article-title>SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication</article-title><source>Nature Communications</source><year>2020</year><volume>11</volume><elocation-id>6059</elocation-id><pub-id pub-id-type="pmcid">PMC7695715</pub-id><pub-id pub-id-type="pmid">33247099</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-19883-7</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shan</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">32225176</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><article-title>Structure of SARS-CoV-2 spike protein</article-title><source>Curr Opin Virol</source><year>2021</year><volume>50</volume><fpage>173</fpage><lpage>182</lpage><pub-id pub-id-type="pmcid">PMC8423807</pub-id><pub-id pub-id-type="pmid">34534731</pub-id><pub-id pub-id-type="doi">10.1016/j.coviro.2021.08.010</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M-Y</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>L-J</given-names></name><name><surname>Gao</surname><given-names>X-F</given-names></name><name><surname>Wang</surname><given-names>D-P</given-names></name><name><surname>Cao</surname><given-names>J-M</given-names></name></person-group><article-title>SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development</article-title><source>Frontiers in Cellular and Infection Microbiology</source><year>2020</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC7723891</pub-id><pub-id pub-id-type="pmid">33324574</pub-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.587269</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>CB</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name></person-group><article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title><source>Nature Reviews Molecular Cell Biology</source><year>2022</year><volume>23</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="pmcid">PMC8491763</pub-id><pub-id pub-id-type="pmid">34611326</pub-id><pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1444</fpage><lpage>1448</lpage><pub-id pub-id-type="pmcid">PMC7164635</pub-id><pub-id pub-id-type="pmid">32132184</pub-id><pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>AG</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group><article-title>Mechanisms of SARS-CoV-2 Transmission and Pathogenesis</article-title><source>Trends Immunol</source><year>2020</year><volume>41</volume><fpage>1100</fpage><lpage>1115</lpage><pub-id pub-id-type="pmcid">PMC7556779</pub-id><pub-id pub-id-type="pmid">33132005</pub-id><pub-id pub-id-type="doi">10.1016/j.it.2020.10.004</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V’kovski</surname><given-names>P</given-names></name><name><surname>Kratzel</surname><given-names>A</given-names></name><name><surname>Steiner</surname><given-names>S</given-names></name><name><surname>Stalder</surname><given-names>H</given-names></name><name><surname>Thiel</surname><given-names>V</given-names></name></person-group><article-title>Coronavirus biology and replication: implications for SARS-CoV-2</article-title><source>Nature Reviews Microbiology</source><year>2021</year><volume>19</volume><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="pmcid">PMC7592455</pub-id><pub-id pub-id-type="pmid">33116300</pub-id><pub-id pub-id-type="doi">10.1038/s41579-020-00468-6</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Tajkhorshid</surname><given-names>E</given-names></name></person-group><article-title>Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors</article-title><source>Proceedings of the National Academy of Sciences</source><year>2022</year><volume>119</volume><elocation-id>e2119761119</elocation-id><pub-id pub-id-type="pmcid">PMC9282386</pub-id><pub-id pub-id-type="pmid">35737823</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2119761119</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production</article-title><source>Front Mol Biosci</source><year>2021</year><volume>8</volume><elocation-id>629873</elocation-id><pub-id pub-id-type="pmcid">PMC8076860</pub-id><pub-id pub-id-type="pmid">33928117</pub-id><pub-id pub-id-type="doi">10.3389/fmolb.2021.629873</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangaru</surname><given-names>S</given-names></name><name><surname>Ozorowski</surname><given-names>G</given-names></name><name><surname>Turner</surname><given-names>HL</given-names></name><name><surname>Antanasijevic</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>1089</fpage><lpage>1094</lpage><pub-id pub-id-type="pmcid">PMC7857404</pub-id><pub-id pub-id-type="pmid">33082295</pub-id><pub-id pub-id-type="doi">10.1126/science.abe1502</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvatori</surname><given-names>G</given-names></name><name><surname>Luberto</surname><given-names>L</given-names></name><name><surname>Maffei</surname><given-names>M</given-names></name><name><surname>Aurisicchio</surname><given-names>L</given-names></name><name><surname>Roscilli</surname><given-names>G</given-names></name><name><surname>Palombo</surname><given-names>F</given-names></name><etal/></person-group><article-title>SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines</article-title><source>Journal of Translational Medicine</source><year>2020</year><volume>18</volume><issue>222</issue><pub-id pub-id-type="pmcid">PMC7268185</pub-id><pub-id pub-id-type="pmid">32493510</pub-id><pub-id pub-id-type="doi">10.1186/s12967-020-02392-y</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternberg</surname><given-names>A</given-names></name><name><surname>Naujokat</surname><given-names>C</given-names></name></person-group><article-title>Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination</article-title><source>Life Sciences</source><year>2020</year><volume>257</volume><elocation-id>118056</elocation-id><pub-id pub-id-type="pmcid">PMC7336130</pub-id><pub-id pub-id-type="pmid">32645344</pub-id><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118056</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Guan</surname><given-names>F</given-names></name><name><surname>Candotti</surname><given-names>F</given-names></name><name><surname>Benlagha</surname><given-names>K</given-names></name><name><surname>Camara</surname><given-names>NOS</given-names></name><name><surname>Herrada</surname><given-names>AA</given-names></name><etal/></person-group><article-title>The role of B cells in COVID-19 infection and vaccination</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><elocation-id>988536</elocation-id><pub-id pub-id-type="pmcid">PMC9468879</pub-id><pub-id pub-id-type="pmid">36110861</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.988536</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>SC</given-names></name></person-group><article-title>T-cell-inducing vaccines - what’s the future</article-title><source>Immunology</source><year>2012</year><volume>135</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="pmcid">PMC3246649</pub-id><pub-id pub-id-type="pmid">22044118</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2567.2011.03517.x</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>P</given-names></name></person-group><article-title>The T cell immune response against SARS-CoV-2</article-title><source>Nature Immunology</source><year>2022</year><volume>23</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">35105982</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayesh</surname><given-names>MEH</given-names></name><name><surname>Kohara</surname><given-names>M</given-names></name><name><surname>Tsukiyama-Kohara</surname><given-names>K</given-names></name></person-group><article-title>An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants</article-title><source>Viruses</source><year>2021</year><volume>13</volume><pub-id pub-id-type="pmcid">PMC8622245</pub-id><pub-id pub-id-type="pmid">34835108</pub-id><pub-id pub-id-type="doi">10.3390/v13112302</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teijaro</surname><given-names>JR</given-names></name><name><surname>Farber</surname><given-names>DL</given-names></name></person-group><article-title>COVID-19 vaccines: modes of immune activation and future challenges</article-title><source>Nature Reviews Immunology</source><year>2021</year><volume>21</volume><fpage>195</fpage><lpage>197</lpage><pub-id pub-id-type="pmcid">PMC7934118</pub-id><pub-id pub-id-type="pmid">33674759</pub-id><pub-id pub-id-type="doi">10.1038/s41577-021-00526-x</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>P</given-names></name><name><surname>Barmania</surname><given-names>F</given-names></name><name><surname>Mellet</surname><given-names>J</given-names></name><name><surname>Peta</surname><given-names>K</given-names></name><name><surname>Strydom</surname><given-names>A</given-names></name><name><surname>Viljoen</surname><given-names>IM</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Variants, Vaccines, and Host Immunity</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><elocation-id>809244</elocation-id><pub-id pub-id-type="pmcid">PMC8761766</pub-id><pub-id pub-id-type="pmid">35046961</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.809244</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKee</surname><given-names>AS</given-names></name><name><surname>Marrack</surname><given-names>P</given-names></name></person-group><article-title>Old and new adjuvants</article-title><source>Current Opinion in Immunology</source><year>2017</year><volume>47</volume><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="pmcid">PMC5724967</pub-id><pub-id pub-id-type="pmid">28734174</pub-id><pub-id pub-id-type="doi">10.1016/j.coi.2017.06.005</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendelac</surname><given-names>A</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><article-title>Adjuvants of Immunity : Harnessing Innate Immunity to Promote Adaptive Immunity</article-title><source>Journal of Experimental Medicine</source><year>2002</year><volume>195</volume><fpage>F19</fpage><lpage>F23</lpage><pub-id pub-id-type="pmcid">PMC2193763</pub-id><pub-id pub-id-type="pmid">11877490</pub-id><pub-id pub-id-type="doi">10.1084/jem.20020073</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>WT</given-names></name><name><surname>Carabelli</surname><given-names>AM</given-names></name><name><surname>Jackson</surname><given-names>B</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Thomson</surname><given-names>EC</given-names></name><name><surname>Harrison</surname><given-names>EM</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title><source>Nature Reviews Microbiology</source><year>2021</year><volume>19</volume><fpage>409</fpage><lpage>424</lpage><pub-id pub-id-type="pmcid">PMC8167834</pub-id><pub-id pub-id-type="pmid">34075212</pub-id><pub-id pub-id-type="doi">10.1038/s41579-021-00573-0</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magazine</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>McGee</surname><given-names>MC</given-names></name><name><surname>Veggiani</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name></person-group><article-title>Mutations and Evolution of the SARS-CoV-2 Spike Protein</article-title><source>Viruses</source><year>2022</year><volume>14</volume><pub-id pub-id-type="pmcid">PMC8949778</pub-id><pub-id pub-id-type="pmid">35337047</pub-id><pub-id pub-id-type="doi">10.3390/v14030640</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DY</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Wheeler</surname><given-names>B</given-names></name><name><surname>Young</surname><given-names>H</given-names></name><name><surname>Holloway</surname><given-names>S</given-names></name><name><surname>Sunny</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><fpage>933</fpage><lpage>941</lpage><pub-id pub-id-type="pmcid">PMC8781317</pub-id><pub-id pub-id-type="pmid">35020982</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2117128</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feikin</surname><given-names>DR</given-names></name><name><surname>Higdon</surname><given-names>MM</given-names></name><name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name><name><surname>Andrews</surname><given-names>N</given-names></name><name><surname>Araos</surname><given-names>R</given-names></name><name><surname>Goldberg</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>924</fpage><lpage>944</lpage><pub-id pub-id-type="pmcid">PMC8863502</pub-id><pub-id pub-id-type="pmid">35202601</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00152-0</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>ST</given-names></name><name><surname>Kwan</surname><given-names>AT</given-names></name><name><surname>Rodríguez-Barraquer</surname><given-names>I</given-names></name><name><surname>Singer</surname><given-names>BJ</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Lewnard</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave</article-title><source>Nature Medicine</source><year>2023</year><volume>29</volume><fpage>358</fpage><lpage>365</lpage><pub-id pub-id-type="pmcid">PMC9974584</pub-id><pub-id pub-id-type="pmid">36593393</pub-id><pub-id pub-id-type="doi">10.1038/s41591-022-02138-x</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erbelding</surname><given-names>EJ</given-names></name><name><surname>Post</surname><given-names>DJ</given-names></name><name><surname>Stemmy</surname><given-names>EJ</given-names></name><name><surname>Roberts</surname><given-names>PC</given-names></name><name><surname>Augustine</surname><given-names>AD</given-names></name><name><surname>Ferguson</surname><given-names>S</given-names></name><etal/></person-group><article-title>A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases</article-title><source>The Journal of Infectious Diseases</source><year>2018</year><volume>218</volume><fpage>347</fpage><lpage>354</lpage><pub-id pub-id-type="pmcid">PMC6279170</pub-id><pub-id pub-id-type="pmid">29506129</pub-id><pub-id pub-id-type="doi">10.1093/infdis/jiy103</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019</article-title><source>Front Microbiol</source><year>2022</year><volume>13</volume><elocation-id>948770</elocation-id><pub-id pub-id-type="pmcid">PMC9271922</pub-id><pub-id pub-id-type="pmid">35832809</pub-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.948770</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aboudounya</surname><given-names>MM</given-names></name><name><surname>Heads</surname><given-names>RJ</given-names></name></person-group><article-title>COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation</article-title><source>Mediators Inflamm</source><year>2021</year><volume>2021</volume><elocation-id>8874339</elocation-id><pub-id pub-id-type="pmcid">PMC7811571</pub-id><pub-id pub-id-type="pmid">33505220</pub-id><pub-id pub-id-type="doi">10.1155/2021/8874339</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabrey</surname><given-names>FL</given-names></name><name><surname>Morrell</surname><given-names>ED</given-names></name><name><surname>Wurfel</surname><given-names>MM</given-names></name></person-group><article-title>TLRs in COVID-19: How they drive immunopathology and the rationale for modulation</article-title><source>Innate Immun</source><year>2021</year><volume>27</volume><fpage>503</fpage><lpage>513</lpage><pub-id pub-id-type="pmcid">PMC8762091</pub-id><pub-id pub-id-type="pmid">34806446</pub-id><pub-id pub-id-type="doi">10.1177/17534259211051364</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanmohammadi</surname><given-names>S</given-names></name><name><surname>Rezaei</surname><given-names>N</given-names></name></person-group><article-title>Role of Toll-like receptors in the pathogenesis of COVID-19</article-title><source>J Med Virol</source><year>2021</year><volume>93</volume><fpage>2735</fpage><lpage>2739</lpage><pub-id pub-id-type="pmcid">PMC8014260</pub-id><pub-id pub-id-type="pmid">33506952</pub-id><pub-id pub-id-type="doi">10.1002/jmv.26826</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Shafiei</surname><given-names>MS</given-names></name><name><surname>Longoria</surname><given-names>C</given-names></name><name><surname>Schoggins</surname><given-names>JW</given-names></name><name><surname>Savani</surname><given-names>RC</given-names></name><name><surname>Zaki</surname><given-names>H</given-names></name></person-group><article-title>SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway</article-title><source>eLife</source><year>2021</year><volume>10</volume><elocation-id>e68563</elocation-id><pub-id pub-id-type="pmcid">PMC8709575</pub-id><pub-id pub-id-type="pmid">34866574</pub-id><pub-id pub-id-type="doi">10.7554/eLife.68563</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>EP</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Fitzpatrick</surname><given-names>E</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><etal/></person-group><article-title>TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines</article-title><source>Nat Immunol</source><year>2021</year><volume>22</volume><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="pmcid">PMC8882317</pub-id><pub-id pub-id-type="pmid">33963333</pub-id><pub-id pub-id-type="doi">10.1038/s41590-021-00937-x</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatraju</surname><given-names>PK</given-names></name><name><surname>Ghassemieh</surname><given-names>BJ</given-names></name><name><surname>Nichols</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Jerome</surname><given-names>KR</given-names></name><name><surname>Nalla</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Covid-19 in Critically Ill Patients in the Seattle Region - Case Series</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>2012</fpage><lpage>2022</lpage><pub-id pub-id-type="pmcid">PMC7143164</pub-id><pub-id pub-id-type="pmid">32227758</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2004500</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>ZM</given-names></name><name><surname>Yang</surname><given-names>MH</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Lian</surname><given-names>ZX</given-names></name><name><surname>Deng</surname><given-names>SL</given-names></name></person-group><article-title>Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><elocation-id>989664</elocation-id><pub-id pub-id-type="pmcid">PMC9518217</pub-id><pub-id pub-id-type="pmid">36188605</pub-id><pub-id pub-id-type="doi">10.3389/fphar.2022.989664</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atalis</surname><given-names>A</given-names></name><name><surname>Keenum</surname><given-names>MC</given-names></name><name><surname>Pandey</surname><given-names>B</given-names></name><name><surname>Beach</surname><given-names>A</given-names></name><name><surname>Pradhan</surname><given-names>P</given-names></name><name><surname>Vantucci</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine</article-title><source>bioRxiv</source><year>2022</year><pub-id pub-id-type="pmcid">PMC9121740</pub-id><pub-id pub-id-type="pmid">35577151</pub-id><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.05.023</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Godfroy</surname><given-names>JI</given-names></name><name><surname>Brown</surname><given-names>PN</given-names></name><name><surname>Kastelowitz</surname><given-names>N</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name></person-group><article-title>Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists</article-title><source>Sci Adv</source><year>2015</year><volume>1</volume><pub-id pub-id-type="pmcid">PMC4474499</pub-id><pub-id pub-id-type="pmid">26101787</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.1400139</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>A</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name></person-group><article-title>In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><fpage>2105</fpage><lpage>2113</lpage><pub-id pub-id-type="pmcid">PMC7267663</pub-id><pub-id pub-id-type="pmid">32383269</pub-id><pub-id pub-id-type="doi">10.1002/jmv.25987</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Burkart</surname><given-names>V</given-names></name><name><surname>Flohe</surname><given-names>S</given-names></name><name><surname>Kolb</surname><given-names>H</given-names></name></person-group><article-title>Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex</article-title><source>J Immunol</source><year>2000</year><volume>164</volume><fpage>558</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">10623794</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Jang</surname><given-names>A</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Yeon</surname><given-names>J</given-names></name><name><surname>Jang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular mechanism underlying the TLR4 antagonistic and antiseptic activities of papiliocin, an insect innate immune response molecule</article-title><source>Proc Natl Acad Sci U S A</source><year>2022</year><volume>119</volume><elocation-id>e2115669119</elocation-id><pub-id pub-id-type="pmcid">PMC8915966</pub-id><pub-id pub-id-type="pmid">35238667</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2115669119</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyavar</surname><given-names>SR</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Emani</surname><given-names>R</given-names></name><name><surname>Pawar</surname><given-names>GP</given-names></name><name><surname>Chaudhari</surname><given-names>VD</given-names></name><name><surname>Podany</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options</article-title><source>Biomed Pharmacother</source><year>2021</year><volume>141</volume><elocation-id>111794</elocation-id><pub-id pub-id-type="pmcid">PMC8189763</pub-id><pub-id pub-id-type="pmid">34153851</pub-id><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111794</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Autocrine interferon priming in macrophages but not dendritic cells results in enhanced cytokine and chemokine production after coronavirus infection</article-title><source>mBio</source><year>2010</year><volume>1</volume><pub-id pub-id-type="pmcid">PMC2957079</pub-id><pub-id pub-id-type="pmid">20978536</pub-id><pub-id pub-id-type="doi">10.1128/mBio.00219-10</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durai</surname><given-names>P</given-names></name><name><surname>Shin</surname><given-names>HJ</given-names></name><name><surname>Achek</surname><given-names>A</given-names></name><name><surname>Kwon</surname><given-names>HK</given-names></name><name><surname>Govindaraj</surname><given-names>RG</given-names></name><name><surname>Panneerselvam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Toll-like receptor 2 antagonists identified through virtual screening and experimental validation</article-title><source>FEBS J</source><year>2017</year><volume>284</volume><fpage>2264</fpage><lpage>2283</lpage><pub-id pub-id-type="pmid">28570013</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname><given-names>K</given-names></name><name><surname>Biggar</surname><given-names>KK</given-names></name><name><surname>Green</surname><given-names>JR</given-names></name></person-group><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.29.014381</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>AR</given-names></name><name><surname>Mallick</surname><given-names>B</given-names></name><name><surname>Sharma</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Chakraborty</surname><given-names>C</given-names></name></person-group><article-title>Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex</article-title><source>Infect Genet Evol</source><year>2020</year><volume>85</volume><elocation-id>104587</elocation-id><pub-id pub-id-type="pmcid">PMC7543713</pub-id><pub-id pub-id-type="pmid">33039603</pub-id><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104587</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardone</surname><given-names>M</given-names></name><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Rosenberg</surname><given-names>AS</given-names></name><name><surname>Puig</surname><given-names>M</given-names></name></person-group><article-title>Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><elocation-id>1131</elocation-id><pub-id pub-id-type="pmcid">PMC7272717</pub-id><pub-id pub-id-type="pmid">32574265</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01131</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustine</surname><given-names>JN</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name></person-group><article-title>Immunopathology of Hyperinflammation in COVID-19</article-title><source>Am J Pathol</source><year>2021</year><volume>191</volume><fpage>4</fpage><lpage>17</lpage><pub-id pub-id-type="pmcid">PMC7484812</pub-id><pub-id pub-id-type="pmid">32919977</pub-id><pub-id pub-id-type="doi">10.1016/j.ajpath.2020.08.009</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Dinesh</surname><given-names>RK</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Rustagi</surname><given-names>A</given-names></name><name><surname>Cousins</surname><given-names>H</given-names></name><name><surname>Zengel</surname><given-names>J</given-names></name><etal/></person-group><article-title>CRISPRa screening with real world evidence identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2021.2007.2001.450475</elocation-id><pub-id pub-id-type="doi">10.1101/2021.07.01.450475</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahiri</surname><given-names>A</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Chakravortty</surname><given-names>D</given-names></name></person-group><article-title>Engagement of TLR signaling as adjuvant: Towards smarter vaccine and beyond</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>6777</fpage><lpage>6783</lpage><pub-id pub-id-type="pmid">18835576</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinhagen</surname><given-names>F</given-names></name><name><surname>Kinjo</surname><given-names>T</given-names></name><name><surname>Bode</surname><given-names>C</given-names></name><name><surname>Klinman</surname><given-names>DM</given-names></name></person-group><article-title>TLR-based immune adjuvants</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>3341</fpage><lpage>3355</lpage><pub-id pub-id-type="pmcid">PMC3000864</pub-id><pub-id pub-id-type="pmid">20713100</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.08.002</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Kunasegaran</surname><given-names>K</given-names></name><name><surname>Tham</surname><given-names>CYL</given-names></name><name><surname>Hafezi</surname><given-names>M</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><etal/></person-group><article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">32668444</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Tarke</surname><given-names>A</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmcid">PMC7574914</pub-id><pub-id pub-id-type="pmid">32753554</pub-id><pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarke</surname><given-names>A</given-names></name><name><surname>Coelho</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>ED</given-names></name><name><surname>Methot</surname><given-names>N</given-names></name><etal/></person-group><article-title>SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>847</fpage><lpage>859</lpage><elocation-id>e811</elocation-id><pub-id pub-id-type="pmcid">PMC8784649</pub-id><pub-id pub-id-type="pmid">35139340</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.015</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>TR</given-names></name><name><surname>Niessl</surname><given-names>J</given-names></name><name><surname>Olofsson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant</article-title><source>Nature Medicine</source><year>2022</year><volume>28</volume><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="pmcid">PMC8938268</pub-id><pub-id pub-id-type="pmid">35042228</pub-id><pub-id pub-id-type="doi">10.1038/s41591-022-01700-x</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeton</surname><given-names>R</given-names></name><name><surname>Tincho</surname><given-names>MB</given-names></name><name><surname>Ngomti</surname><given-names>A</given-names></name><name><surname>Baguma</surname><given-names>R</given-names></name><name><surname>Benede</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><etal/></person-group><article-title>T cell responses to SARS-CoV-2 spike cross-recognize Omicron</article-title><source>Nature</source><year>2022</year><volume>603</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="pmcid">PMC8930768</pub-id><pub-id pub-id-type="pmid">35102311</pub-id><pub-id pub-id-type="doi">10.1038/s41586-022-04460-3</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Shin</surname><given-names>EC</given-names></name></person-group><article-title>Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2</article-title><source>Immune Netw</source><year>2022</year><volume>22</volume><fpage>e29</fpage><pub-id pub-id-type="pmcid">PMC9433189</pub-id><pub-id pub-id-type="pmid">36081529</pub-id><pub-id pub-id-type="doi">10.4110/in.2022.22.e29</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rennert</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>McMahan</surname><given-names>CS</given-names></name><name><surname>Dean</surname><given-names>D</given-names></name></person-group><article-title>Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults</article-title><source>Nature Communications</source><year>2022</year><volume>13</volume><elocation-id>3946</elocation-id><pub-id pub-id-type="pmcid">PMC9263799</pub-id><pub-id pub-id-type="pmid">35803915</pub-id><pub-id pub-id-type="doi">10.1038/s41467-022-31469-z</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>PA</given-names></name><name><surname>Olsen</surname><given-names>RJ</given-names></name><name><surname>Long</surname><given-names>SW</given-names></name><name><surname>Snehal</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>JJ</given-names></name><name><surname>Ojeda Saavedra</surname><given-names>M</given-names></name><etal/></person-group><article-title>Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas</article-title><source>The American Journal of Pathology</source><year>2022</year><volume>192</volume><fpage>642</fpage><lpage>652</lpage><pub-id pub-id-type="pmcid">PMC8812084</pub-id><pub-id pub-id-type="pmid">35123975</pub-id><pub-id pub-id-type="doi">10.1016/j.ajpath.2022.01.007</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chenchula</surname><given-names>S</given-names></name><name><surname>Karunakaran</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Chavan</surname><given-names>M</given-names></name></person-group><article-title>Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review</article-title><source>J Med Virol</source><year>2022</year><volume>94</volume><fpage>2969</fpage><lpage>2976</lpage><pub-id pub-id-type="pmcid">PMC9088621</pub-id><pub-id pub-id-type="pmid">35246846</pub-id><pub-id pub-id-type="doi">10.1002/jmv.27697</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meggiolaro</surname><given-names>A</given-names></name><name><surname>Sane Schepisi</surname><given-names>M</given-names></name><name><surname>Farina</surname><given-names>S</given-names></name><name><surname>Castagna</surname><given-names>C</given-names></name><name><surname>Mammone</surname><given-names>A</given-names></name><name><surname>Siddu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis</article-title><source>Expert Rev Vaccines</source><year>2022</year><volume>21</volume><fpage>1831</fpage><lpage>1841</lpage><pub-id pub-id-type="pmid">36242513</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmer</surname><given-names>B</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Gran</surname><given-names>B</given-names></name><name><surname>Pinilla</surname><given-names>C</given-names></name><name><surname>Cortese</surname><given-names>I</given-names></name><name><surname>Pascal</surname><given-names>J</given-names></name><etal/></person-group><article-title>Minimal peptide length requirements for CD4+ T cell clones—implications for molecular mimicry and T cell survival</article-title><source>International Immunology</source><year>2000</year><volume>12</volume><fpage>375</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">10700472</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stryhn</surname><given-names>A</given-names></name><name><surname>Kongsgaard</surname><given-names>M</given-names></name><name><surname>Rasmussen</surname><given-names>M</given-names></name><name><surname>Harndahl</surname><given-names>MN</given-names></name><name><surname>Osterbye</surname><given-names>T</given-names></name><name><surname>Bassi</surname><given-names>MR</given-names></name><etal/></person-group><article-title>A Systematic, Unbiased Mapping of CD8(+) and CD4(+) T Cell Epitopes in Yellow Fever Vaccinees</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>1836</fpage><pub-id pub-id-type="pmcid">PMC7489334</pub-id><pub-id pub-id-type="pmid">32983097</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01836</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>KL</given-names></name><name><surname>Reits</surname><given-names>E</given-names></name><name><surname>Neefjes</surname><given-names>J</given-names></name></person-group><article-title>Present Yourself! By MHC Class I and MHC Class II Molecules</article-title><source>Trends Immunol</source><year>2016</year><volume>37</volume><fpage>724</fpage><lpage>737</lpage><pub-id pub-id-type="pmcid">PMC5159193</pub-id><pub-id pub-id-type="pmid">27614798</pub-id><pub-id pub-id-type="doi">10.1016/j.it.2016.08.010</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neefjes</surname><given-names>J</given-names></name><name><surname>Jongsma</surname><given-names>MLM</given-names></name><name><surname>Paul</surname><given-names>P</given-names></name><name><surname>Bakke</surname><given-names>O</given-names></name></person-group><article-title>Towards a systems understanding of MHC class I and MHC class II antigen presentation</article-title><source>Nature Reviews Immunology</source><year>2011</year><volume>11</volume><fpage>823</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">22076556</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piazza</surname><given-names>A</given-names></name><name><surname>Menozzi</surname><given-names>P</given-names></name><name><surname>Cavalli-Sforza</surname><given-names>LL</given-names></name></person-group><article-title>The HLA-A,B gene frequencies in the world: Migration or selection?</article-title><source>Human Immunology</source><year>1980</year><volume>1</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">7263314</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodmer</surname><given-names>J</given-names></name></person-group><article-title>World distribution of HLA alleles and implications for disease</article-title><source>Ciba Found Symp</source><year>1996</year><volume>197</volume><fpage>233</fpage><lpage>253</lpage><comment>discussion 253-238</comment><pub-id pub-id-type="pmid">8827377</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Teng</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><elocation-id>e0144475</elocation-id><pub-id pub-id-type="pmcid">PMC4671582</pub-id><pub-id pub-id-type="pmid">26641892</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0144475</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Carter</surname><given-names>B</given-names></name><name><surname>Bricken</surname><given-names>T</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Viard</surname><given-names>M</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><etal/></person-group><article-title>Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions</article-title><source>Cell Systems</source><year>2020</year><volume>11</volume><fpage>131</fpage><lpage>144</lpage><elocation-id>e136</elocation-id><pub-id pub-id-type="pmcid">PMC7384425</pub-id><pub-id pub-id-type="pmid">32721383</pub-id><pub-id pub-id-type="doi">10.1016/j.cels.2020.06.009</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poran</surname><given-names>A</given-names></name><name><surname>Harjanto</surname><given-names>D</given-names></name><name><surname>Malloy</surname><given-names>M</given-names></name><name><surname>Rooney</surname><given-names>MS</given-names></name><name><surname>Srinivasan</surname><given-names>L</given-names></name><name><surname>Gaynor</surname><given-names>RB</given-names></name></person-group><article-title>Sequence-based prediction of vaccine targets for inducing T cell responses to SARS-CoV-2 utilizing the bioinformatics predictor RECON</article-title><source>bioRxiv</source><year>2020</year><elocation-id>2020.2004.2006.027805</elocation-id><pub-id pub-id-type="doi">10.1101/2020.04.06.027805</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CC</given-names></name><name><surname>Olsen</surname><given-names>KS</given-names></name><name><surname>Gentry</surname><given-names>KM</given-names></name><name><surname>Sambade</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>W</given-names></name><name><surname>Garness</surname><given-names>J</given-names></name><etal/></person-group><article-title>Landscape and selection of vaccine epitopes in SARS-CoV-2</article-title><source>Genome Medicine</source><year>2021</year><volume>13</volume><fpage>101</fpage><pub-id pub-id-type="pmcid">PMC8201469</pub-id><pub-id pub-id-type="pmid">34127050</pub-id><pub-id pub-id-type="doi">10.1186/s13073-021-00910-1</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vita</surname><given-names>R</given-names></name><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Overton</surname><given-names>JA</given-names></name><name><surname>Dhanda</surname><given-names>SK</given-names></name><name><surname>Martini</surname><given-names>S</given-names></name><name><surname>Cantrell</surname><given-names>JR</given-names></name><etal/></person-group><article-title>The Immune Epitope Database (IEDB): 2018 update</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><fpage>D339</fpage><lpage>D343</lpage><pub-id pub-id-type="pmcid">PMC6324067</pub-id><pub-id pub-id-type="pmid">30357391</pub-id><pub-id pub-id-type="doi">10.1093/nar/gky1006</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Scheuermann</surname><given-names>RH</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><article-title>A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2</article-title><source>Cell Host &amp; Microbe</source><year>2020</year><volume>27</volume><fpage>671</fpage><lpage>680</lpage><elocation-id>e672</elocation-id><pub-id pub-id-type="pmcid">PMC7142693</pub-id><pub-id pub-id-type="pmid">32183941</pub-id><pub-id pub-id-type="doi">10.1016/j.chom.2020.03.002</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokal</surname><given-names>A</given-names></name><name><surname>Chappert</surname><given-names>P</given-names></name><name><surname>Barba-Spaeth</surname><given-names>G</given-names></name><name><surname>Roeser</surname><given-names>A</given-names></name><name><surname>Fourati</surname><given-names>S</given-names></name><name><surname>Azzaoui</surname><given-names>I</given-names></name><etal/></person-group><article-title>Maturation and persistence of the anti-SARS-CoV-2 memory B cell response</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>1201</fpage><lpage>1213</lpage><elocation-id>e1214</elocation-id><pub-id pub-id-type="pmcid">PMC7994111</pub-id><pub-id pub-id-type="pmid">33571429</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2021.01.050</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Röltgen</surname><given-names>K</given-names></name><name><surname>Boyd</surname><given-names>SD</given-names></name></person-group><article-title>Antibody and B cell responses to SARS-CoV-2 infection and vaccination</article-title><source>Cell Host &amp; Microbe</source><year>2021</year><volume>29</volume><fpage>1063</fpage><lpage>1075</lpage><pub-id pub-id-type="pmcid">PMC8233571</pub-id><pub-id pub-id-type="pmid">34174992</pub-id><pub-id pub-id-type="doi">10.1016/j.chom.2021.06.009</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreano</surname><given-names>E</given-names></name><name><surname>Paciello</surname><given-names>I</given-names></name><name><surname>Piccini</surname><given-names>G</given-names></name><name><surname>Manganaro</surname><given-names>N</given-names></name><name><surname>Pileri</surname><given-names>P</given-names></name><name><surname>Hyseni</surname><given-names>I</given-names></name><etal/></person-group><article-title>Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants</article-title><source>Nature</source><year>2021</year><volume>600</volume><fpage>530</fpage><lpage>535</lpage><pub-id pub-id-type="pmcid">PMC8674140</pub-id><pub-id pub-id-type="pmid">34670266</pub-id><pub-id pub-id-type="doi">10.1038/s41586-021-04117-7</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Drabek</surname><given-names>D</given-names></name><name><surname>Okba</surname><given-names>NMA</given-names></name><name><surname>van Haperen</surname><given-names>R</given-names></name><name><surname>Osterhaus</surname><given-names>ADME</given-names></name><etal/></person-group><article-title>A human monoclonal antibody blocking SARS-CoV-2 infection</article-title><source>Nature Communications</source><year>2020</year><volume>11</volume><fpage>2251</fpage><pub-id pub-id-type="pmcid">PMC7198537</pub-id><pub-id pub-id-type="pmid">32366817</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-16256-y</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>CO</given-names></name><name><surname>Jette</surname><given-names>CA</given-names></name><name><surname>Abernathy</surname><given-names>ME</given-names></name><name><surname>Dam</surname><given-names>K-MA</given-names></name><name><surname>Esswein</surname><given-names>SR</given-names></name><name><surname>Gristick</surname><given-names>HB</given-names></name><etal/></person-group><article-title>SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies</article-title><source>Nature</source><year>2020</year><volume>588</volume><fpage>682</fpage><lpage>687</lpage><pub-id pub-id-type="pmcid">PMC8092461</pub-id><pub-id pub-id-type="pmid">33045718</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2852-1</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiaojie</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>lei</surname><given-names>Y</given-names></name><name><surname>Guang</surname><given-names>Y</given-names></name><name><surname>Min</surname><given-names>Q</given-names></name></person-group><article-title>Neutralizing antibodies targeting SARS-CoV-2 spike protein</article-title><source>Stem Cell Research</source><year>2021</year><volume>50</volume><fpage>102125</fpage><pub-id pub-id-type="pmcid">PMC7737530</pub-id><pub-id pub-id-type="pmid">33341604</pub-id><pub-id pub-id-type="doi">10.1016/j.scr.2020.102125</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Ryu</surname><given-names>D-K</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>Y-I</given-names></name><name><surname>Seo</surname><given-names>J-M</given-names></name><name><surname>Kim</surname><given-names>Y-G</given-names></name><etal/></person-group><article-title>A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein</article-title><source>Nature Communications</source><year>2021</year><volume>12</volume><fpage>288</fpage><pub-id pub-id-type="pmcid">PMC7803729</pub-id><pub-id pub-id-type="pmid">33436577</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-20602-5</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Nair</surname><given-names>MS</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Rapp</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">32698192</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reily</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>TJ</given-names></name><name><surname>Renfrow</surname><given-names>MB</given-names></name><name><surname>Novak</surname><given-names>J</given-names></name></person-group><article-title>Glycosylation in health and disease</article-title><source>Nature Reviews Nephrology</source><year>2019</year><volume>15</volume><fpage>346</fpage><lpage>366</lpage><pub-id pub-id-type="pmcid">PMC6590709</pub-id><pub-id pub-id-type="pmid">30858582</pub-id><pub-id pub-id-type="doi">10.1038/s41581-019-0129-4</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>HJ</given-names></name><name><surname>Froehlich</surname><given-names>JW</given-names></name><name><surname>Lebrilla</surname><given-names>CB</given-names></name></person-group><article-title>Determination of glycosylation sites and site-specific heterogeneity in glycoproteins</article-title><source>Curr Opin Chem Biol</source><year>2009</year><volume>13</volume><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="pmcid">PMC2749913</pub-id><pub-id pub-id-type="pmid">19700364</pub-id><pub-id pub-id-type="doi">10.1016/j.cbpa.2009.07.022</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>P</given-names></name></person-group><article-title>Golgi glycosylation</article-title><source>Cold Spring Harb Perspect Biol</source><year>2011</year><volume>3</volume><pub-id pub-id-type="pmcid">PMC3062213</pub-id><pub-id pub-id-type="pmid">21441588</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a005199</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>GW</given-names></name><name><surname>Haltiwanger</surname><given-names>RS</given-names></name><name><surname>Holt</surname><given-names>GD</given-names></name><name><surname>Kelly</surname><given-names>WG</given-names></name></person-group><article-title>Glycosylation in the nucleus and cytoplasm</article-title><source>Annu Rev Biochem</source><year>1989</year><volume>58</volume><fpage>841</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">2673024</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marth</surname><given-names>JD</given-names></name><name><surname>Grewal</surname><given-names>PK</given-names></name></person-group><article-title>Mammalian glycosylation in immunity</article-title><source>Nature Reviews Immunology</source><year>2008</year><volume>8</volume><fpage>874</fpage><lpage>887</lpage><pub-id pub-id-type="pmcid">PMC2768770</pub-id><pub-id pub-id-type="pmid">18846099</pub-id><pub-id pub-id-type="doi">10.1038/nri2417</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>The use of lectin microarray for assessing glycosylation of therapeutic proteins</article-title><source>MAbs</source><year>2016</year><volume>8</volume><fpage>524</fpage><lpage>535</lpage><pub-id pub-id-type="pmcid">PMC4966825</pub-id><pub-id pub-id-type="pmid">26918373</pub-id><pub-id pub-id-type="doi">10.1080/19420862.2016.1149662</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chawla</surname><given-names>H</given-names></name><name><surname>Jossi</surname><given-names>SE</given-names></name><name><surname>Faustini</surname><given-names>SE</given-names></name><name><surname>Samsudin</surname><given-names>F</given-names></name><name><surname>Allen</surname><given-names>JD</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic</article-title><source>Journal of Molecular Biology</source><year>2022</year><volume>434</volume><elocation-id>167332</elocation-id><pub-id pub-id-type="pmcid">PMC8550889</pub-id><pub-id pub-id-type="pmid">34717971</pub-id><pub-id pub-id-type="doi">10.1016/j.jmb.2021.167332</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Maurya</surname><given-names>VK</given-names></name><name><surname>Prasad</surname><given-names>AK</given-names></name><name><surname>Bhatt</surname><given-names>MLB</given-names></name><name><surname>Saxena</surname><given-names>SK</given-names></name></person-group><article-title>Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)</article-title><source>VirusDisease</source><year>2020</year><volume>31</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmcid">PMC7085496</pub-id><pub-id pub-id-type="pmid">32206694</pub-id><pub-id pub-id-type="doi">10.1007/s13337-020-00571-5</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shental-Bechor</surname><given-names>D</given-names></name><name><surname>Levy</surname><given-names>Y</given-names></name></person-group><article-title>Effect of glycosylation on protein folding: a close look at thermodynamic stabilization</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>8256</fpage><lpage>8261</lpage><pub-id pub-id-type="pmcid">PMC2448824</pub-id><pub-id pub-id-type="pmid">18550810</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0801340105</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonzom</surname><given-names>C</given-names></name><name><surname>Hüttner</surname><given-names>S</given-names></name><name><surname>Mirgorodskaya</surname><given-names>E</given-names></name><name><surname>Chong</surname><given-names>S-L</given-names></name><name><surname>Uthoff</surname><given-names>S</given-names></name><name><surname>Steinbüchel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Glycosylation influences activity, stability and immobilization of the feruloyl esterase 1a from Myceliophthora thermophila</article-title><source>AMB Express</source><year>2019</year><volume>9</volume><issue>126</issue><pub-id pub-id-type="pmcid">PMC6691016</pub-id><pub-id pub-id-type="pmid">31407106</pub-id><pub-id pub-id-type="doi">10.1186/s13568-019-0852-z</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Allen</surname><given-names>JD</given-names></name><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Crispin</surname><given-names>M</given-names></name></person-group><article-title>Site-specific glycan analysis of the SARS-CoV-2 spike</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>330</fpage><lpage>333</lpage><pub-id pub-id-type="pmcid">PMC7199903</pub-id><pub-id pub-id-type="pmid">32366695</pub-id><pub-id pub-id-type="doi">10.1126/science.abb9983</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name></person-group><article-title>The glycosylation in SARS-CoV-2 and its receptor ACE2</article-title><source>Signal Transduction and Targeted Therapy</source><year>2021</year><volume>6</volume><issue>396</issue><pub-id pub-id-type="pmcid">PMC8591162</pub-id><pub-id pub-id-type="pmid">34782609</pub-id><pub-id pub-id-type="doi">10.1038/s41392-021-00809-8</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanda</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>L</given-names></name><name><surname>Goldman</surname><given-names>R</given-names></name></person-group><article-title>N- and O-Glycosylation of the SARS-CoV-2 Spike Protein</article-title><source>Anal Chem</source><year>2021</year><volume>93</volume><fpage>2003</fpage><lpage>2009</lpage><pub-id pub-id-type="pmcid">PMC7805595</pub-id><pub-id pub-id-type="pmid">33406838</pub-id><pub-id pub-id-type="doi">10.1021/acs.analchem.0c03173</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>CA</given-names></name><name><surname>Tauber</surname><given-names>R</given-names></name><name><surname>Blanchard</surname><given-names>V</given-names></name></person-group><article-title>Glycosylation is a key in SARS-CoV-2 infection</article-title><source>Journal of Molecular Medicine</source><year>2021</year><volume>99</volume><fpage>1023</fpage><lpage>1031</lpage><pub-id pub-id-type="pmcid">PMC8140746</pub-id><pub-id pub-id-type="pmid">34023935</pub-id><pub-id pub-id-type="doi">10.1007/s00109-021-02092-0</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wintjens</surname><given-names>R</given-names></name><name><surname>Bifani</surname><given-names>AM</given-names></name><name><surname>Bifani</surname><given-names>P</given-names></name></person-group><article-title>Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein</article-title><source>NPJ Vaccines</source><year>2020</year><volume>5</volume><issue>81</issue><pub-id pub-id-type="pmcid">PMC7474083</pub-id><pub-id pub-id-type="pmid">32944295</pub-id><pub-id pub-id-type="doi">10.1038/s41541-020-00237-9</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dacon</surname><given-names>C</given-names></name><name><surname>Tucker</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>CD</given-names></name><name><surname>Lin</surname><given-names>TH</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Broadly neutralizing antibodies target the coronavirus fusion peptide</article-title><source>Science</source><year>2022</year><volume>377</volume><fpage>728</fpage><lpage>735</lpage><pub-id pub-id-type="pmcid">PMC9348754</pub-id><pub-id pub-id-type="pmid">35857439</pub-id><pub-id pub-id-type="doi">10.1126/science.abq3773</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanda</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>L</given-names></name><name><surname>Goldman</surname><given-names>R</given-names></name></person-group><article-title>N- and O-Glycosylation of the SARS-CoV-2 Spike Protein</article-title><source>Analytical Chemistry</source><year>2021</year><volume>93</volume><fpage>2003</fpage><lpage>2009</lpage></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brun</surname><given-names>J</given-names></name><name><surname>Vasiljevic</surname><given-names>S</given-names></name><name><surname>Gangadharan</surname><given-names>B</given-names></name><name><surname>Hensen</surname><given-names>MV</given-names></name><name><surname>Chandran</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike</article-title><source>ACS Central Science</source><year>2021</year><volume>7</volume><fpage>586</fpage><lpage>593</lpage><pub-id pub-id-type="pmcid">PMC8029450</pub-id><pub-id pub-id-type="pmid">34056088</pub-id><pub-id pub-id-type="doi">10.1021/acscentsci.1c00058</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><etal/></person-group><article-title>O-Glycosylation Landscapes of SARS-CoV-2 Spike Proteins</article-title><source>Front Chem</source><year>2021</year><volume>9</volume><elocation-id>689521</elocation-id><pub-id pub-id-type="pmcid">PMC8450404</pub-id><pub-id pub-id-type="pmid">34552909</pub-id><pub-id pub-id-type="doi">10.3389/fchem.2021.689521</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins</article-title><source>Molecular &amp; Cellular Proteomics</source><year>2021</year><volume>20</volume><elocation-id>100058</elocation-id><pub-id pub-id-type="pmcid">PMC7876485</pub-id><pub-id pub-id-type="pmid">33077685</pub-id><pub-id pub-id-type="doi">10.1074/mcp.RA120.002295</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sikora</surname><given-names>M</given-names></name><name><surname>von Bulow</surname><given-names>S</given-names></name><name><surname>Blanc</surname><given-names>FEC</given-names></name><name><surname>Gecht</surname><given-names>M</given-names></name><name><surname>Covino</surname><given-names>R</given-names></name><name><surname>Hummer</surname><given-names>G</given-names></name></person-group><article-title>Computational epitope map of SARS-CoV-2 spike protein</article-title><source>PLoS Comput Biol</source><year>2021</year><volume>17</volume><elocation-id>e1008790</elocation-id><pub-id pub-id-type="pmcid">PMC8016105</pub-id><pub-id pub-id-type="pmid">33793546</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008790</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H-Y</given-names></name><name><surname>Liao</surname><given-names>H-Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S-W</given-names></name><name><surname>Cheng</surname><given-names>C-W</given-names></name><name><surname>Shahed-Al-Mahmud</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models</article-title><source>Science Translational Medicine</source><year>2022</year><volume>14</volume><elocation-id>eabm0899</elocation-id><pub-id pub-id-type="pmcid">PMC9802656</pub-id><pub-id pub-id-type="pmid">35230146</pub-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abm0899</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C-Y</given-names></name><name><surname>Cheng</surname><given-names>C-W</given-names></name><name><surname>Kung</surname><given-names>C-C</given-names></name><name><surname>Liao</surname><given-names>K-S</given-names></name><name><surname>Jan</surname><given-names>J-T</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><etal/></person-group><article-title>Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine</article-title><source>Proceedings of the National Academy of Sciences</source><year>2022</year><volume>119</volume><elocation-id>e2119995119</elocation-id><pub-id pub-id-type="pmcid">PMC8892489</pub-id><pub-id pub-id-type="pmid">35149556</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2119995119</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>EG</given-names></name><name><surname>Lustig</surname><given-names>Y</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Fluss</surname><given-names>R</given-names></name><name><surname>Indenbaum</surname><given-names>V</given-names></name><name><surname>Amit</surname><given-names>S</given-names></name><etal/></person-group><article-title>Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><elocation-id>e84</elocation-id><pub-id pub-id-type="pmcid">PMC8522797</pub-id><pub-id pub-id-type="pmid">34614326</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2114583</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kingstad-Bakke</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Chandrasekar</surname><given-names>SS</given-names></name><name><surname>Gasper</surname><given-names>DJ</given-names></name><name><surname>Salas-Quinchucua</surname><given-names>C</given-names></name><name><surname>Cleven</surname><given-names>T</given-names></name><etal/></person-group><article-title>Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants</article-title><source>Proc Natl Acad Sci U S A</source><year>2022</year><volume>119</volume><elocation-id>e2118312119</elocation-id><pub-id pub-id-type="pmcid">PMC9171754</pub-id><pub-id pub-id-type="pmid">35561224</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2118312119</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Shuai</surname><given-names>ZW</given-names></name><name><surname>Ye</surname><given-names>DQ</given-names></name><etal/></person-group><article-title>New-onset autoimmune phenomena post-COVID-19 vaccination</article-title><source>Immunology</source><year>2022</year><volume>165</volume><fpage>386</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">34957554</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gracia-Ramos</surname><given-names>AE</given-names></name><name><surname>Martin-Nares</surname><given-names>E</given-names></name><name><surname>Hernández-Molina</surname><given-names>G</given-names></name></person-group><article-title>New Onset of Autoimmune Diseases Following COVID-19 Diagnosis</article-title><source>Cells</source><year>2021</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC8700122</pub-id><pub-id pub-id-type="pmid">34944099</pub-id><pub-id pub-id-type="doi">10.3390/cells10123592</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vita</surname><given-names>R</given-names></name><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Overton</surname><given-names>JA</given-names></name><name><surname>Dhanda</surname><given-names>SK</given-names></name><name><surname>Martini</surname><given-names>S</given-names></name><name><surname>Cantrell</surname><given-names>JR</given-names></name><etal/></person-group><article-title>The Immune Epitope Database (IEDB): 2018 update</article-title><source>Nucleic Acids Research</source><year>2018</year><volume>47</volume><fpage>D339</fpage><lpage>D343</lpage></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Ansari</surname><given-names>HR</given-names></name><name><surname>Gautam</surname><given-names>A</given-names></name><name><surname>Raghava</surname><given-names>GPS</given-names></name></person-group><article-title>Open Source Drug Discovery, C. Identification of B-cell epitopes in an antigen for inducing specific class of antibodies</article-title><source>Biology Direct</source><year>2013</year><volume>8</volume><issue>27</issue><pub-id pub-id-type="pmcid">PMC3831251</pub-id><pub-id pub-id-type="pmid">24168386</pub-id><pub-id pub-id-type="doi">10.1186/1745-6150-8-27</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>CD</given-names></name><name><surname>So</surname><given-names>RTY</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><etal/></person-group><article-title>A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>630</fpage><lpage>633</lpage><pub-id pub-id-type="pmcid">PMC7164391</pub-id><pub-id pub-id-type="pmid">32245784</pub-id><pub-id pub-id-type="doi">10.1126/science.abb7269</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>MC</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><name><surname>Marcatili</surname><given-names>P</given-names></name></person-group><article-title>BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><fpage>W24</fpage><lpage>w29</lpage><pub-id pub-id-type="pmcid">PMC5570230</pub-id><pub-id pub-id-type="pmid">28472356</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkx346</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Schematics of Spike structure and SARS-CoV-2 infection</title><p>(A) Structure of the SARS-CoV-2 Spike protein (PDB ID 6VXX). (B) Diagram of SARS-CoV-2 Spike (S) gene. NTD: N-terminal domain; RBD: receptor-binding domain; FP: fusion peptide; HR1: heptad repeat 1; HR2: heptad repeat 2; TM: transmembrane region; IC: intracellular domain. (C) The primary mechanism of SARS-CoV-2 cell entry and propagation.</p></caption><graphic xlink:href="EMS190346-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>A general overview of host immune responses to Spike-based vaccines</title><p>Upon host exposure to Spike-based vaccines, antigen-presenting cells (APCs) sample, process, and present the antigens to CD4<sup>+</sup> and CD8<sup>+</sup> T cells via MHCII and MHCI respectively. Activated CD4<sup>+</sup> T cells can differentiate into follicular helper T (Tfh) and type 1 T helper (Th1) cells which further mediate B cell activation and plasma cell maturation. Th1 cells also aid in priming APC activation and maturation to enhance antigen presentation. Activated CD8<sup>+</sup> T cells also receive assistance from Th1 cells to potentiate development into cytotoxic T lymphocytes (CTLs). While plasma cell-produced antibodies can neutralize viruses and bind to infected cells to mediate antibody-associated cell death, CTLs function through direct contact to eliminate infected cells. Therefore, Spike-based vaccine-induced antibodies and T cells provide protective immunity against SARS-CoV-2 infections.</p></caption><graphic xlink:href="EMS190346-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Toll-like receptor interacting epitopes in SARS-CoV-2 Spike</title><p>Sites on SARS-CoV-2 Spike protein interacting with TLR1 (A), TLR4 (B), and TLR6 (C). Inset shows full-length Spike protein with a circle indicating the relative position of zoomed in area. Sites interacting via hydrophobic interaction or hydrogen bonding are displayed in black or red respectively. (D) List of the TLR-interacting sites, interaction type, TLR interaction, genetic entropy of all reposited sequences, and genetic entropy relative to Omicron strain BA.5. Blue boxes indicate experimentally confirmed TLR-interacting sites. Sites with Shannon entropy (SE) exceeding 0.05 bear substantial variation among the described SARS-CoV-2 strains.</p></caption><graphic xlink:href="EMS190346-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>T cell receptor immune epitopes in SARS-CoV-2 Spike</title><p>(A) List of T cell receptor interacting epitopes, starting/ending positions, frequency of response as seen in experimental assays (T cell activation or peptide/tetramer binding), mean residue genetic entropy of all reposited sequences, mean residue genetic entropy relative to Omicron strain BA.5, and mean residue solvent accessibility. The frequency of response represents the proportion of positive assays as compared to the total number of assays for a given epitope (higher being more common) with data obtained from <ext-link ext-link-type="uri" xlink:href="https://iedb.org/">IEDB.org</ext-link>. Genetic entropy was calculated based on the Shannon entropy (SE) of GISAID-reposited SARS-CoV-2 sequences and is reported as the mean calculated residue entropy through the given epitope. Solvent accessibility is reported as mean square-angstroms of solvent accessibility for residues through each epitope. (B) Sites on the SARS-CoV-2 Spike reported to have T cell receptor interaction. Surface regions are displayed in magenta; some residues are not on the surface and are occluded by the colored domains, becoming purple or violet; some residues cannot be shown due to their inaccessibility on the structure resolved.</p></caption><graphic xlink:href="EMS190346-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>B cell receptor/antibody immune epitopes in SARS-CoV-2 Spike</title><p>Comparison of linear epitopes (A) observed as binding targets and (B) experimentally validated as neutralizing antibody epitopes, by antibodies found in database-reposited SARS-CoV-2 patient sera. The first nine amino acid sequences of the epitopes, starting/ending positions, mean genetic entropy of all trains, mean genetic entropy of BA.5, and mean residue solvent accessibility are shown. Genetic entropy was calculated based on the Shannon entropy (SE) of GISAID reposited SARS-CoV-2 sequences. Values are reported as the mean calculated residue entropy through the given epitope. Solvent accessibility is reported as mean square-angstroms of solvent accessibility for residues through each epitope. (C) Sites linear epitopes of neutralizing antibodies on the SARS-CoV-2 Spike protein. Surface regions are displayed in magenta; some residues are not on the surface and are occluded by the colored domains, becoming purple or violet; some residues cannot be shown due to their inaccessibility on the structure resolved.</p></caption><graphic xlink:href="EMS190346-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Glycosites and their relations with immune epitopes in SARS-CoV-2 Spike</title><p>(A) List of glycosites, linkage type, overlaps with immune epitopes interacting with TLRs, TCR or BCR, proportion of IgG epitope overlap from patient serum, proportion of IgA overlap from patient serum, and genetic entropy of all reposited sequences or only those of the Omicron BA.5 subset. IgA/IgG overlap is reported as the percentage of observed patient-serum antibodies which overlap with a given site. (B) Glycosylated sites of the SARS-CoV-2 Spike protein. Some residues cannot be shown due to their absence from the resolved structure. O-linked and N-linked sites are displayed in black and red respectively. (C) Plots of predicted relative antigenicity over SARS-CoV-2 Spike protein for both glycosylated and deglycosylated Spike. Glycosites are denoted with vertical blue lines. (D) Immune epitope map of SARS-CoV-2 Spike protein. TLR, T cell, and B cell epitopes are displayed. Glycosites are depicted with vertical red lines.</p></caption><graphic xlink:href="EMS190346-f006"/></fig></floats-group></article>